388 related articles for article (PubMed ID: 24621801)
1. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
2. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
3. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
7. [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
Grellety T; Brugères-Chakiba C; Chaminade A; Roubaud G; Ravaud A; Gross-Goupil M
Bull Cancer; 2014 Jun; 101(6):608-18. PubMed ID: 24977449
[TBL] [Abstract][Full Text] [Related]
8. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.
Schmidinger M; Bergler-Klein J
Int J Urol; 2012 Sep; 19(9):796-804. PubMed ID: 22583077
[TBL] [Abstract][Full Text] [Related]
9. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
10. Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Chorianopoulos E; Jäger D; Katus HA; Frey N
Clin Res Cardiol; 2007 Nov; 96(11):829-30. PubMed ID: 17694380
[No Abstract] [Full Text] [Related]
11. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
14. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
[TBL] [Abstract][Full Text] [Related]
15. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
17. [Adverse event profile of new targeted agents for renal cell carcinoma].
Nozawa M; Uemura H
Hinyokika Kiyo; 2012 Nov; 58(11):655-7. PubMed ID: 23254796
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL
J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
20. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]